Specialist-based treatment reduces the severity of allergic rhinitis
Article first published online: 21 JUN 2013
© 2013 John Wiley & Sons Ltd
Clinical & Experimental Allergy
Volume 43, Issue 7, pages 723–729, July 2013
How to Cite
Clinical & Experimental Allergy, 2013; (43)723–729., , , , , .
- Issue published online: 21 JUN 2013
- Article first published online: 21 JUN 2013
- Accepted manuscript online: 7 JAN 2013 01:10PM EST
- Manuscript Accepted: 21 DEC 2012
- Manuscript Revised: 20 DEC 2012
- Manuscript Received: 20 MAR 2012
- quality of life;
- modified ARIA classification;
- allergic rhinitis;
Although the treatment of allergic rhinitis (AR) is now well established, its impact on severity has not yet been evaluated.
The aim was to analyse specialist-based treatment on AR severity, nasal symptoms and quality of life.
A longitudinal observational, prospective, multi-centre study with 4 weeks of follow-up was carried out by 141 allergologists and ENT specialists in Spain. Selection criteria were adult patients with AR, clinically diagnosed at least 2 years before, with a total nasal symptom score (TNSS) ≥5, not receiving either antihistamines within the previous week or nasal corticosteroids during the 2 previous weeks. Disease severity using both original Allergic Rhinitis and its Impact on Asthma (o-ARIA) and modified (m-ARIA) classifications, nasal symptoms, and Quality of Life (ESPRINT-15), were measured at baseline and after 4 weeks of treatment.
Among the recruited AR patients (n = 707, 58% women), 39.3% were intermittent and 60.7% persistent, 40.2% had asthma and 61.4% conjunctivitis. Most patients were treated with second generation antihistamines in monotherapy (63.2%) or in combination with intranasal corticosteroids (31.5%). While using o-ARIA, 96.9% of patients had ‘moderate/severe’ AR, the m-ARIA discriminated between ‘moderate’ (55.4%) and severe (41.5%) AR, at baseline. After 4 weeks of treatment, improvement was found on disease severity (P < 0.0001), TNSS (8.2 ± 1.8 vs. 3.5 ± 2.3, P < 0.0001) and Quality of Life (ESPRINT-15 global score: 3.0 ± 1.2 vs. 1.1 ± 1.0, P < 0.0001).
Specialist-based treatment reduces AR severity, evaluated using the m-ARIA classification for the first time, in addition to the improvement of nasal symptoms and quality of life.
Specialist-based treatment improves AR severity, in addition to nasal symptoms and quality of life. However, no matter the treatment option some AR patients remain severe and need further follow-up.